News about "Innovent Biologics"

Innovent Collaborates with Lilly to Develop New Medicines in Oncology and Immunology

The agreement grants Lilly an exclusive licence to develop and commercialise the programmes worldwide outside Greater China, while Innovent retains rights in Greater China.

Innovent Biologics | 09/02/2026 | By News Bureau

Innovent's Tri-Specific Antibody IBI3003 Secures FDA Fast Track Status for Relapsed/Refractory Multiple Myeloma

Innovent Biologics’ tri-specific antibody IBI3003 has received FDA Fast Track Designation for heavily pretreated relapsed or refractory multiple myeloma, supported by promising early clinical efficacy and safety data.

Innovent Biologics | 27/01/2026 | By News Bureau |  107

Innovent TABOSUN Becomes China's First Approved Domestic Anti CTLA 4 Antibody

Innovent Biologics has received approval from China’s National Medical Products Administration (NMPA) for TABOSUN (Ipilimumab N01 Injection), marking the country’s first domestically developed anti-CTLA-4 monoclonal antibody and a significant milestone in China’s immuno-oncology landscape.

Innovent Biologics | 26/12/2025 | By News Bureau |  143

Innovent Biologics and Takeda Finalise Global Collaboration for Next-Generation IO and ADC Therapies

As part of the agreement, Takeda will pay Innovent an upfront payment of USD1.2 billion, including a USD100 million equity investment at HKD112.56 per share.

Innovent Biologics | 05/12/2025 | By Dineshwori

Innovent's PECONDLE Becomes China's First Approved IL-23p19 Antibody

Innovent has received NMPA approval for PECONDLE (picankibart injection), marking China’s first IL-23p19 monoclonal antibody to be cleared for treating moderate-to-severe plaque psoriasis in adults eligible for systemic therapy.

Innovent Biologics | 02/12/2025 | By Dineshwori |  163

Innovent Gets Second Fast Track Designation from FDA for IBI363

This designation applies to the treatment of unresectable, locally advanced, or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed following anti-PD-(L)1 immune checkpoint inhibitor therapy and platinum-based chemotherapy.

Innovent Biologics | 17/02/2025 | By Aishwarya |  284

Innovent's DOVBLERON Secures Second NMPA Approval for ROS1-Positive NSCLC

China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON®, a next-generation ROS1 tyrosine kinase inhibitor (TKI).

Innovent Biologics | 03/01/2025 | By Abha |  258

Mankind Pharma, Innovent Biologics to Commercialize Sintilimab for Cancer Care

This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.

Innovent Biologics | 27/12/2024 | By Aishwarya |  336

Innovent Partners with Ask Pharm for Limertinib for Treatment of Lung Cancer

Under the agreement, Innovent will obtain the exclusive commercialization rights for limertinib in mainland China, and will be entitled to receive a commercialization service fee based on the product's net sales in the region.

Innovent Biologics | 08/10/2024 | By Aishwarya |  503

Innovent Secures Fast Track Designation from FDA for IBI363

Innovent Biologics has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to its PD-1/IL-2α Bispecific Antibody Fusion Protein for the treatment of unresectable locally advanced or metastatic melanoma.

Innovent Biologics | 04/09/2024 | By Aishwarya |  589